Efectos secundarios en el uso de inhibidores de cotransportadores de sodio y glucosa en el tratamiento de Diabetes Mellitus Tipo 2

Abstract

According to epidemiological data, approximately 23.5 million people worldwide suffer from type 2 diabetes mellitus, which poses serious challenges for healthcare systems, as well as for the management and achievement of sustained metabolic regulation. Treatment with SGLT2 inhibitors ―a novel non-insulin therapy that helps maintain glycemic control― has been shown to cause adverse effects, primarily associated with the onset of genitourinary infections, diabetic ketoacidosis, bladder cancer, and bone disorders. Objective: To collect bibliographic information on the “Side Effects of Using Sodium- glucose Cotransporter Inhibitors in the Treatment of Type 2 Diabetes Mellitus.” Expected Results: The use of SGLT2 inhibitors has been proven to have clinically significant adverse effects, including diabetic ketoacidosis, nephropathies, genitourinary infections, and osteoporosis, which were the most important ones identified in this review.